Abstract
BackgroundAtopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety profile in pregnancy.Case presentationWe report a case of severe atopic dermatitis treated safely with dupilumab with no adverse maternal or fetal outcomes and resolution of atopic dermatitis postpartum in the absence of maintenance dupilumab therapy.ConclusionHere we demonstrate the safe use of dupilumab in pregnancy. Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy.
Highlights
Here we demonstrate the safe use of dupilumab in pregnancy
Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy
Atopic dermatitis (AD), a chronic inflammatory skin disorder that manifests with severe pruritis in the setting of eczematous lesions, is one of the most common skin disorders in adults and children
Summary
Atopic dermatitis (AD), a chronic inflammatory skin disorder that manifests with severe pruritis in the setting of eczematous lesions, is one of the most common skin disorders in adults and children. Conclusion: Here we demonstrate the safe use of dupilumab in pregnancy. Current treatment options for moderate to severe AD in pregnancy include oral corticosteroids, azathioprine, cyclosporine and phototherapy [3, 8]. There remains a paucity of data evaluating the impact of dupilumab in the pregnant population and the subsequent effects on fetal outcomes [10].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
